
	Version PDF

Improvement of atopic dermatitis skin symptoms by Vitreoscilla filiformis bacterial extract

European Journal of Dermatology. Volume 16, Numéro 4, 380-4, July-August 2006, Therapy

Summary

Auteur(s) : Audrey Guéniche, Anca Hennino, Catherine Goujon, Karima Dahel, Philippe Bastien, Richard Martin, Roland Jourdain, Lionel Breton , L’OREAL Recherche, Clichy, France, Clinical Immunology and Allergology, Lyon-Sud Hospital, Pierre Bénite and INSERM U503, IFR 128, Lyon, France, L’Oréal Recherche, Aulnay-sous-bois, France, C/O CRN, L’OREAL, Notre Dame D’OE, France.

Illustrations

Figure 1 Clinical improvement of atopic skin symptoms. 95% CI delta treated versus vehicle in Modified Eczema Area and Severity Index (mEASI) (A), EASI (B), pruritus severity (C) and body surface area (constant A) (D). The mEASI considers the affected body surface area and the severity of erythema, edema, excoriations, lichenification (EASI) and itching. Y-axis unit represent delta values of the mean of EASI with their corresponding confidence interval (mean ± 2 SEM) and error bars represent 2SEM.

Figure 2 Modified Eczema Area and Severity Index (mEASI). At Day 28, change from baseline to the end of treatment for Vitreoscilla filiformis treated side showed a 42.9% decrease in mEASI whereas the vehicle treated side showed a decrease by 24.8% (p = 0.008) (*). Y-axis unit represent the mean of mEASI and error bars represent 2 SEM.

Figure 3 Clinical presentation of patient 1 (A, B) and 7 (C, D), before (A, C) and at the end (B, D) of the treatment.V.f. extract is in the left in the figure.